2022-502311-12-00已完成2 期
"neoBREASTIM": A Phase 2 Study of Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer (TNBC)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- Safety run-in: The incidence, nature and severity of adverse events, with severity graded according to NCI CTCAE v5.0
研究概览
简要总结
Safety run-in: To evaluate safety and toxicity of the combination Atezolizumab plus RP1 oncolytic immunotherapy. Phase II: To evaluate the rate of Residual Cancer Burden (RCB) 0-1, as assessed by local pathologist, at the time of definitive surgery in subjects with early TNBC who have completed at least one cycle of treatment.
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Follow-up period 2
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Female subject
- •Agreement to perform blood samples at screening, on-treatment, and at surgery for immune monitoring and translational research activities
- •Adequate bone marrow function as defined below (Laboratory Parameters realized within 14 days before inclusion): Absolute neutrophil count ≥1500/µL, i.e. 1.5x109/L; Hemoglobin ≥ 9.0 g/dL; Platelets ≥100000/µL, i.e. 100x109/L
- •Adequate liver function as defined below (Laboratory Parameters realized within 14 days before inclusion): Serum total bilirubin ≤ 1.5 x ULN. In case of known Gilbert’s syndrome ≤ 3 x UNL is allowed; AST (SGOT) ≤ 3.0 x ULN; ALT (SGPT) ≤ 3.0 x ULN
- •Adequate renal function as defined below (Laboratory Parameters realized within 14 days before inclusion): Creatinine ≤ 1.5 x UNL or eGFR≥40ml/min/1.73m^2
- •Adequate coagulant function as defined below (Laboratory Parameters realized within 14 days before inclusion): International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 x ULN; Partial Thromboplastin Time (PTT) or activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN
- •Left ventricular ejection fraction (LVEF) ≥ 50% by cardiac ultrasound. LVEF performed in routine is accepted if done within 28 days prior to the beginning of screening
- •Serum pregnancy test (for subjects of childbearing potential) negative within 72 hours prior to first dose of study administration
- •Women of childbearing potential (WOCBP)* must agree to use 1 highly effective method of contraception during the screening period, during the treatment of the study and at least 6 months after the last administration of study treatment. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period
- •Signed Informed Consent form (ICF) obtained prior to any study procedure
- •Affiliated to Social Security System.
- •Age ≥ 18 years old
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1
- •Newly diagnosed Triple-Negative Breast Cancer (TNBC), defined as the absence of ER expression and PR expression, and of HER2 overexpression, must be determined by local testing of a screening tumor sample as defined by ASCO/CAP guidelines
- •TNBC defined as the following combined primary tumor (T), regional lymph node (N), and metastatic (M) AJCC staging criteria: cT ≥15 - ≤30 mm, N0, M0 according to Mammogram, breast Ultrasound and MRI, and PET-CT. In case of a difference in the measurement of the primary tumor among different imaging methods, the breast MRI measurement is the reference
- •Unicentric, unifocal and unilateral disease
- •Tumor-infiltrating lymphocytes (TILs) ≥ 30%, as defined by the International TILs Working Group 2014
- •ctDNA dosing at baseline
- •Agreement to provide tissue samples (biopsy at screening and on-treatment), and at surgery for immune monitoring and translational research activities
排除标准
- •Inflammatory breast cancer.
- •Known history of, or any evidence of active, non-infectious pneumonitis.
- •Active infection including: Tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice) - Hepatitis B (known positive HBV surface antigen (HBsAg) result). Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. - Hepatitis C. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. - HIV infection.
- •Has a history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years.
- •Any excipient in RP1 or Atezolizumab known to induce allergic reaction.
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction transient ischemic attack, congestive heart failure or cerebral vascular accident within the previous 12 months, unstable arrhythmias, and/or unstable angina.
- •Medical condition requiring current systemic anticoagulation, or a history of congenital hypercoagulable condition. Subjects taking aspirin at doses < 325 mg per day are eligible provided that prothrombin time is within the institutional range of normal. Use of local anticoagulation for port maintenance is permitted.
- •Diabetes mellitus Type 1 or poorly controlled Type 2 diabetes mellitus defined as a screening hemoglobin A1C ≥ 8 % or a fasting plasma glucose ≥ 160 mg/dL (or 8.8 mmol/L).
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the subject to give written informed consent.
- •History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Prior organ transplantation.
- •Prior treatment with an oncolytic virus-based therapy.
- •Subjects with urinary outflow obstruction.
- •Contraindication to breast MRI (magnetic resonance imaging) and PET scan (positron emission tomography).
- •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to inclusion or 4 weeks after the end of treatment.
- •Pregnant and/or lactating women.
- •Subject with a significant medical, neuro-psychiatric, substance abuse or surgical condition, currently uncontrolled by treatment, which, in the principal investigator’s opinion, may interfere with completion of the study.
- •Vulnerable persons according to the article L.1121-6 of the CSP (Public Health Code), adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the CSP.
- •Patients with active significant herpetic infections or prior complications of HSV-1 infection (e.g., herpetic keratitis, encephalitis, or disseminated herpes infection). Note: patients who suffer from sporadic cold sore lesions may be enrolled as long as no active lesions are present at the time of inclusion. See Management of Herpes Infections of the protocole for further guidance.
- •Patients who require intermittent or chronic use of systemic (oral or IV) antivirals with known antiherpetic activity (e.g., acyclovir).
- •Diagnosis of immunodeficiency.
- •Has active autoimmune disease (e.g. inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis, celiac disease, Wegener’s granulomatosis) that has required systemic treatment in the past 3 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Note: Subjects with childhood atopy or asthma, vitiligo, alopecia, Graves’s disease, Hashimoto’s thyroiditis, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc...) is not considered a form of systemic treatment.
- •Prior systemic immunosuppressive medication (except physiologic corticosteroid replacement therapy) within 30 days of planned start of study therapy.
- •Any live (attenuated) vaccine within 14 days of planned start of study therapy.
- •Prior immunotherapy, including tumor vaccine, cytokine, anti-CTLA4, PD-1/PD-L1 blockade or similar agents, TCR-based or CAR-T cell based adoptive cell therapy.
结局指标
主要结局
Safety run-in: The incidence, nature and severity of adverse events, with severity graded according to NCI CTCAE v5.0
Safety run-in: The incidence, nature and severity of adverse events, with severity graded according to NCI CTCAE v5.0
Phase II: Residual cancer burden RCB 0-1 rate at time of surgery in patients with no increase in ctDNA after cycle 3.
Phase II: Residual cancer burden RCB 0-1 rate at time of surgery in patients with no increase in ctDNA after cycle 3.
次要结局
- The safety and toxicity of the combination therapy will be estimated from the treatment start to the surgery, in terms of duration and severity based on CTCAE v5.0, among all evaluable patients with less than 3 cycles
- The rate of RCB 0-1 will be estimated with its 95% exact confidence interval; among patients with no increase in ctDNA after cycle 3
- The safety and toxicity of the combination therapy will be estimated from the treatment start to the surgery, in terms of duration and severity based on CTCAE v5.0, among patients with no increase in ctDNA after cycle 3
- Invasive disease-free survival (iDFS) in all evaluable subjects will be estimated using the Kaplan-Meier method. iDFS is defined as the time from the date of inclusion to the date of loco-regional relapse, distant relapse, or death, whatever happens first; for patients without such events, the date of last contact will be used, among patients with no increase in ctDNA after cycle 3
- The percentage of TILs will be estimated and compared between RCB rates 0-1 versus 2-3; TILs will be assessed according to the International TILs Working Group 2014 2 and the RCB 0-1 rate according to Symmans et al.1; Among patients with no increase in ctDNA after cycle 3
- The pre-treatment expression of PD-L1 (continuous variable and dichotomous variable) will be estimated and compared between RCB rates 0-1 versus 2-3; PD-L1 expression will be assessed using the PD-L1 IHC SP142 assay with the IC scoring system, among patients with no increase in ctDNA after cycle 3
- Association between RCB rates and response by PET-CT or breast MRI will be studied, among patients with no increase in ctDNA after cycle 3
- To correlate the response by breast MRI with RCB 0-1 rates, among patients with no increase in ctDNA after cycle 3
- The rate of Breast Conservation Surgery (BCS) will be presented, among patients with no increase in ctDNA after cycle 3
- Association between RCB rates and response by radiomics analyses, among patients with no increase in ctDNA after cycle 3
- For the patients with increase in ctDNA after cycle 3 and treated by standard therapeutic approach (3 patients expected), the rate of patients with increased ctDNA and a descriptive analysis of this population will be performed.
研究者
Emanuela ROMANO
Scientific
Institut Curie
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)2023-503568-18-00F. Hoffmann-La Roche AG377
招募中
2 期
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer.Non-small Cell Lung Cancer2022-502738-18-00Beigene Ltd., Beigene Ltd., Beigene Ltd.22
招募中
2 期
A Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non−Small Cell Lung Cancer who have already received chemotherapy and radiotherapy2023-503756-27-00F. Hoffmann-La Roche AG13
已完成
2 期
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapseAcute myeloid leukemia2024-513956-14-00Technische Universitaet Dresden28
招募中
2 期
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma2023-503418-63-00Beigene Ltd.28